Multiparticulate Dual-Release Combination Tablets: A Promising Approach for Chronomodulated and Patient -Centric Drug Delivery
Abstract
Multiparticulate dual-release combination tablets represent an advanced drug delivery platform designed to optimize therapeutic outcomes and enhance patient compliance by synchronizing drug release with the body’s circadian rhythms. These systems incorporate both immediate-release (IR) and controlled/modified-release (CR/MR) components within a single dosage form, ensuring a rapid onset of action followed by sustained drug release over an extended period. This dual functionality is particularly beneficial in managing chronic and time-dependent diseases such as hypertension, asthma, and arthritis, where symptom severity varies throughout the day. Typically, these formulations employ multiparticulate technologies such as pellets, granules, or mini-tablets, which are either filled into capsules or compressed into tablets. Such approaches provide several advantages, including uniform drug distribution, reduced risk of dose dumping, improved gastrointestinal transit, and flexible modulation of release profiles. Various formulation strategies—such as polymer coating, extrusion-spheronization, and compression coating—are used to achieve the desired release kinetics. Evaluation of these systems involves parameters like flow properties, hardness, friability, drug content, dissolution studies, and stability testing to ensure consistent performance and product quality. Importantly, multiparticulate dual-release systems offer patient-centric benefits, including reduced dosing frequency, minimized side effects, and improved adherence to therapy. With ongoing advancements in novel polymers and drug delivery technologies, these systems hold significant promise for chronotherapeutic applications and personalized medicine, paving the way for more effective and targeted treatment strategies .
Keywords: Multiparticulate system, Dual release tablet, Immediate release, Sustained release, Diltiazem hydrochloride, Hydrochlorothiazide, Combination therapy.
Keywords:
Multiparticulate system, Immediate release, Sustained release, Diltiazem hydrochloride, Hydrochlorothiazide, Combination therapyDOI
https://doi.org/10.22270/jddt.v16i7.7893References
1. Aulton ME, Taylor K. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Elsevier; 2018.
2. Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Lippincott Williams & Wilkins; 2014.
3. Sharma RB, Kumar A, Dixit A. A Modern Approach on Mouth Dissolving Drug Technology: Film-Based Oral Delivery. Journal of Drug Delivery & Therapeutics. 2025;15(8):307-314. https://doi.org/10.22270/jddt.v15i8.7346
4. Streubel A, Siepmann J, Bodmeier R. Multiple unit oral dosage forms: a review. J Control Release. 2006;118(2):216-231.
5. Jadhav A, Nagaraj K. Surfactant-enabled nanocarriers in breast cancer therapy: Targeted delivery and multidrug resistance reversal. Pharmaceutics. 2025 Jun 13;17(6):779. https://doi.org/10.3390/pharmaceutics17060779 PMid:40574091 PMCid:PMC12197182
6. Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: current perspectives. J Control Release. 2009;134(2):74-80. https://doi.org/10.1016/j.jconrel.2008.11.011 PMid:19105973
7. Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst. 2001;18(5):433-458. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v18.i5.10 PMid:11763497
8. Maroni A, Zema L, Cerea M, Sangalli ME. Oral pulsatile drug delivery systems. Expert Opin Drug Deliv. 2005;2(5):855-871. https://doi.org/10.1517/17425247.2.5.855 PMid:16296783
9. Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter WR. Developing Solid Oral Dosage Forms. Academic Press; 2009.
10. Siepmann J, Siepmann F. Mathematical modeling of drug delivery. Int J Pharm. 2008;364(2):328-343. https://doi.org/10.1016/j.ijpharm.2008.09.004 PMid:18822362
11. Deshmukh VN. Mouth dissolving drug delivery system: a review. Int J PharmTech Res. 2012;4(1):412-421.
12. Patel A, Patel NM. Multiparticulate systems: a novel approach in drug delivery. Int J Pharm Sci Rev Res. 2010;3(2):45-52.
13. Gazzaniga A, Maroni A, Sangalli ME. Time-controlled oral drug delivery systems. Expert Opin Drug Deliv. 2006;3(5):583-597. https://doi.org/10.1517/17425247.3.5.583 PMid:16948555
14. Shidhaye SS, Lotlikar VM, Ghule AE. Chronotherapeutics and novel drug delivery systems. Int J Pharm Sci Rev Res. 2010;3(2):10-19.
15. Lemmer B. Chronopharmacokinetics: implications for drug treatment. J Pharm Pharmacol. 1999;51(8):887-890. https://doi.org/10.1211/0022357991773294 PMid:10504025
16. Butler CT, Rodgers AM, Curtis AM, Donnelly RF. Chrono-tailored drug delivery systems: recent advances and future directions. Drug Deliv Transl Res. 2024;14:1756-1775. https://doi.org/10.1007/s13346-024-01539-4 PMid:38416386 PMCid:PMC11153310
17. Kole S, Vinchurkar R, Desai R, Wagh P, Marne A, Karnik H, et al. Multi-pulse chronotherapeutic approaches for circadian rhythm disease management. Chronobiol Int. 2025;42(10):1-24. https://doi.org/10.1080/07420528.2025.2546008 PMid:40823912
18. Zeeshan M, Hu J, Mao CX, Danish A, Xiong Y, Irshad MS, et al. Nanomaterial-enabled drug delivery systems for circadian medicine: bridging direct rhythm modulation and chronotherapy. RSC Adv. 2025;15:31981-32008. https://doi.org/10.1039/D5RA04137F PMid:40917604 PMCid:PMC12412127
19. Singh D, Thakur A. Spatiotemporal nanocarriers for circadian-aligned drug delivery: advances, challenges, and future directions. Assay Drug Dev Technol. 2026;24(3):189-205. https://doi.org/10.1177/1540658X251410476 PMid:41979242
20. Garg S, Walters B, Fernandez DC. Chronobiomaterials for circadian-aligned brain therapeutics. Trends Pharmacol Sci. 2026. https://doi.org/10.1016/j.tips.2026.05.005 PMid:42285786
21. Kharat SS, Patil MP. Chronotherapeutic drug delivery using solid lipid nanoparticles. J Chem Health Risks. 2024;14(1).
22. Rajput A, Pingale P, Telange D. Pulsatile drug delivery system: drug journey based on chronobiology. Heliyon. 2024;10:e29064. https://doi.org/10.1016/j.heliyon.2024.e29064 PMid:38813204 PMCid:PMC11133509
23. Ohdo S. Chronopharmacology and chronotherapy: impact of circadian rhythms on drug pharmacokinetics and pharmacodynamics. Biochem Pharmacol. 2020;178:114045. https://doi.org/10.1016/j.bcp.2020.114045 PMid:32446886
24. Youan BBC. Chronopharmaceutical drug delivery systems: Hurdles, hype or hope? Adv Drug Deliv Rev. 2021;178:113996.
25. Smolensky MH, Lemmer B, Reinberg A. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Adv Drug Deliv Rev. 2020;153:70-88.
26. Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2020;60:377-400. https://doi.org/10.1146/annurev.pharmtox.48.113006.094626 PMid:20055686 PMCid:PMC12206864
27. Lin SY, Kawashima Y. Current status and approaches to developing press-coated chronodelivery drug systems. J Control Release. 2021;336:451-467.
28. Khan S, Minhas MU, Tekko IA, Donnelly RF. Nanocarriers for chronotherapeutics. Int J Pharm. 2022;620:121726.
29. Vyas SP, Khar RK. Targeted and controlled drug delivery: novel carrier systems. CBS Publishers; 2021.
30. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling of controlled drug release from matrix systems. Acta Pol Pharm. 2021;78(1):5-17.
31. Patel GM, Patel MM. Emerging trends in multiparticulate drug delivery systems. Drug Dev Ind Pharm. 2022;48(4):521-538.
32. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery. J Control Release. 2020;63:235-259. https://doi.org/10.1016/S0168-3659(99)00204-7 PMid:10601721
33. Verma RK, Garg S. Current status of drug delivery technologies and future directions. Pharm Technol. 2021;45(2):24-36.
34. Park K. Controlled drug delivery systems: past forward and future back. J Control Release. 2021;190:3-8. https://doi.org/10.1016/j.jconrel.2014.03.054 PMid:24794901 PMCid:PMC4142099
35. Rambabu S, Ranawat MS, Bhandari A, Dinesh P. The study of Guar gum and starch on disintegration time and drug release of fast dissolving tablet in rabbit using single dose randomized parallel design method. Jordan Journal of Pharmaceutical Sciences. 2013 8;6(3):280-91. https://doi.org/10.12816/0001506
36. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: a review. J Drug Deliv Sci Technol. 2021;63:102442.
37. Fu Q, Sun J, Zhang W. Stimuli-responsive drug delivery systems for chronotherapy. Biomaterials. 2023;293:121939.
38. Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery. Adv Drug Deliv Rev. 2022;65:104-120. https://doi.org/10.1016/j.addr.2012.10.003 PMid:23088863 PMCid:PMC3565095
39. Kaur G, Rath G, Goyal AK. Oral controlled drug delivery systems: a review. J Drug Target. 2020;28(2):113-130.
40. Chavanpatil MD, Jain P, Chaudhari S. Development of sustained release multiparticulate system. AAPS PharmSciTech. 2021;22:45.
41. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2020;13:123-133. https://doi.org/10.1016/S0928-0987(01)00095-1 PMid:11297896
42. Goyanes A, Buanz ABM, Basit AW, Gaisford S. 3D printing of medicines: engineering novel oral devices. Adv Drug Deliv Rev. 2021;158:33-52.
43. Xu X, Khan MA, Burgess DJ. Predictive dissolution modeling for drug delivery systems. J Pharm Sci. 2022;111(5):1235-1248.
44. Liu F, Merchant HA, Kulkarni RP. Evolution of oral controlled release dosage forms. Int J Pharm. 2020;589:119861.
45. Tran TH, Ramasamy T, Choi JY. Smart drug delivery systems for chronotherapy. Int J Nanomedicine. 2023;18:1123-1145.
46. Wang Y, Li P, Truong-Dinh Tran T. Circadian rhythm-based drug delivery systems: recent advances. Pharmaceutics. 2022;14(3):563.
47. Patel A, Shah D, Mehta T. Chronotherapeutic drug delivery systems: current status and future outlook. J Control Release. 2023;350:948-968.
48. Alqahtani MS, Kazi M, Alsenaidy MA. Advances in oral drug delivery systems. Saudi Pharm J. 2021;29(4):321-330. https://doi.org/10.3389/fphar.2021.618411 PMid:33679401 PMCid:PMC7933596
49. Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2020;86:215-223. https://doi.org/10.1016/j.yexmp.2008.12.004 PMid:19186176 PMCid:PMC3249419
50. Bansal S, Beg S, Asthana A. Multiparticulate drug delivery systems: technological advancements. Expert Opin Drug Deliv. 2022;19(6):645-662.
51. ICH. (2003). Q1A(R2): Stability testing of new drug substances and products. International Council for Harmonisation.
52. Aulton, M. E., & Taylor, K. (2018). Aulton’s pharmaceutics: The design and manufacture of medicines (5th ed.). Elsevier.
53. Waterman, K. C., & Adami, R. C. (2005). Accelerated aging: Prediction of chemical stability of pharmaceuticals. International Journal of Pharmaceutics, 293(1-2), 101-125. https://doi.org/10.1016/j.ijpharm.2004.12.013 PMid:15778049
54. ICH. (2003). Q1A(R2): Stability testing of new drug substances and products. International Council for Harmonisation.
55. Aulton, M. E., & Taylor, K. (2018). Aulton’s pharmaceutics: The design and manufacture of medicines (5th ed.). Elsevier.
56. Waterman, K. C., & Adami, R. C. (2005). Accelerated aging: Prediction of chemical stability of pharmaceuticals. International Journal of Pharmaceutics, 293(1-2), 101-125. https://doi.org/10.1016/j.ijpharm.2004.12.013 PMid:15778049
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Prerona Das , Jyoti Gupta , Rambabu Sharma
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.